We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHC icon
126
Acadia Healthcare
ACHC
$3.16B
– –
-10,000
Closed -$326K
IBB icon
127
iShares Biotechnology ETF
IBB
$9.33B
– –
-13,500
Closed -$1.44M
INO icon
128
Inovio Pharmaceuticals
INO
$88.9M
– –
-11,675
Closed -$579K
LABU icon
129
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$599M
– –
-1,920
Closed -$2.99M
LLY icon
130
Eli Lilly
LLY
$1.05T
– –
-241,262
Closed -$20.4M
QGEN icon
131
Qiagen
QGEN
$8.43B
– –
-53,387
Closed -$1.75M
HIND
132
Vyome Holdings
HIND
$15.2M
– –
0
– -$317K
TBPH icon
133
Theravance Biopharma
TBPH
$877M
– –
-10,628
Closed -$296K
THC icon
134
Tenet Healthcare
THC
$16.8B
– –
-616,796
Closed -$9.34M
UTHR icon
135
United Therapeutics
UTHR
$22.6B
– –
-17,200
Closed -$2.54M
MLNT
136
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-6,420
Closed -$507K
HZNP
137
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-794,062
Closed -$11.6M
EVHC
138
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-13,026
Closed -$450K
BIVV
139
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-10,200
Closed -$550K
JUNO
140
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-41,900
Closed -$1.92M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.